Efficacy and Safety of Thrombopoietin Receptor Agonists in Modern Treatment of Immune Thrombocytopenia

Pârvu, Andrada

doi:10.31925/farmacia.2021.2.5

Cited by 1 publication

(1 citation statement)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to statistics, the overall mortality rate caused by blood disorders is as high as 17.7%. Among them, thrombocytopenia is one of the difficulties in clinical management, and there is currently a lack of effective therapeutic drugs [28,29]. T cells and B cells are dysfunctional in SLE patients, leading to confusion about immune mechanisms.…”

Section: Sensitivity Analysismentioning

confidence: 99%

Meta-Analysis on the Efficacy and Safety of Belimumab for Lupus Nephritis by Using the Pubmed Database

CHEN

2023

FARMACIA

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic autoimmune connective tissue disease associated with loss of immunological tolerance (LIT). Lupus nephritis (LN) is a serious manifestation of SLE, affecting the majority of patients and posing a significant threat to the well-being and survival of SLE patients. More research and evidence are needed to determine whether belimumab can be used to treat active LN, as data on the safety and efficacy of belimumab in the treatment of active LN are currently lacking. The search criteria utilised were "belimumab", "lupus nephritis", "systemic lupus erythematosus" and "lupus treatment". The search was limited to articles published between January 2000 and May 2022. The analysis and evaluation were performed using Rev Man 5.3 and Stata, the risk of bias (RoB) of the included articles was assessed, and the heterogeneity was assessed using the Q-test and the I2 statistics. The results showed that in the 6 included references, the OR for efficacy of belimumab in the treatment of LN was 0.30, the OR for safety was 0.22, and no heterogeneity was observed between study groups (I2 = 0.00%; I2 = 0.00%). The OR for renal involvement of belimumab in the treatment of LN was -0.22, and the OR for complications was -0.37, indicating apparent heterogeneity (I2 = 54.46%; I2 = 30.79%). The heterogeneity gap was small, indicating credible results after further testing. Belimumab treatment was safer in LN, renal involvement was less severe in LN receiving belimumab treatment, and the likelihood of complications was lower in LN receiving belimumab treatment. RezumatLupusul eritematos sistemic (LES) este o boală autoimună cronică a țesutului conjunctiv asociată cu pierderea toleranței imunologice. Nefrita indusă de lupus (NL) este o complicație majoră a LES. Datele actuale privind siguranța și eficacitatea belimumabului în tratamentul LN activ sunt limitate, necesitând mai multe cercetări și dovezi pentru a susține utilizarea acestuia. Utilizând termenii "belimumab", "nefrita indusă de lupus", "lupus eritematos sistemic" și "tratament pentru lupus" au fost căutate articolele relevante publicate din ianuarie 2000 până în aprilie 2022. Analiza și evaluarea acestora au fost efectuate cu ajutorul Rev Man 5.3 și Stata. A fost evaluat indicele RoB al articolelor incluse, iar heterogenitatea a fost evaluată cu ajutorul testului Q și I2. Rezultatele au arătat că, în cele 6 referințe incluse, OR pentru eficacitatea belimumabului în tratamentul LN a fost de 0,30, OR pentru siguranță a fost de 0,22 și nu s-a observat nicio heterogenitate între grupurile de studiu (I2 = 0,00%; I2 = 0,00%). OR pentru implicarea renală a belimumabului în tratamentul LN a fost de -0,22, iar OR pentru complicații a fost de -0,37, indicând o heterogenitate aparentă (I2 = 54,46%; I2 = 30,79%). Nivelul de eterogenitate al datelor a fost scăzut, ceea ce sugerează că rezultatele sunt credibile și pot fi confirmate prin teste suplimentare. Tratamentul cu belimumab a fost asociat cu un profil de siguranță îmbunătățit în LN, cu o afect...

show abstract

Section: Sensitivity Analysismentioning

confidence: 99%

Meta-Analysis on the Efficacy and Safety of Belimumab for Lupus Nephritis by Using the Pubmed Database

CHEN

2023

FARMACIA

View full text Add to dashboard Cite

show abstract

Efficacy and Safety of Thrombopoietin Receptor Agonists in Modern Treatment of Immune Thrombocytopenia

Cited by 1 publication

References 72 publications

Meta-Analysis on the Efficacy and Safety of Belimumab for Lupus Nephritis by Using the Pubmed Database

Meta-Analysis on the Efficacy and Safety of Belimumab for Lupus Nephritis by Using the Pubmed Database

Contact Info

Product

Resources

About